Detection of the tau protein in human serum by a sensitive four-electrode electrochemical biosensor by Wang, Scarlet Xiaoyan et al.
1Detection of the tau protein in human serum by a sensitive four-
electrode electrochemical biosensor
Scarlet Xiaoyan Wang1, Desiree Acha1, Ajit J Shah1, Frank Hills1, Ivan Roitt1, Andreas
Demosthenous2, Richard H Bayford1*
1 Department of Natural Sciences, Middlesex University, UK
2 Department of Electronic and Electrical Engineering, University College London, UK.
*Corresponding author. Tel: +44(0)7771773140. Email: r.bayford@mdx.ac.uk
Abstract
This study presents a novel approach based on a four-electrode electrochemical biosensor for the
detection of tau protein - one of the possible markers for the prediction of Alzheimer’s disease (AD).
The biosensor is based on the formation of stable antibody–antigen complexes on gold microband
electrodes covered with a layer of a self-assembled monolayer and protein G. Antibodies were
immobilized on the gold electrode surface in an optimal orientation by protein G interaction.
Electrochemical impedance spectroscopy was used to analyze impedance change, which revealed a
linear response with increasing tau concentrations. The assay is fast (<1 h for incubation and
measurement) and very sensitive. The limit of quantification for the full-length 2N4R tau protein is
0.03 pM, a value unaltered when the assay was processed in bovine serum albumin or human serum.
This technology could be adapted for the detection of other biomarkers to provide a multiple assay to
identify AD progression in a point of care setting.
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1. Introduction
Alzheimer’s disease (AD) is the most common form of dementia, with an estimated 37 million
sufferers worldwide and is expected to affect 115 million by 2050 if no effective therapeutic strategies
are developed (Wimo et al., 2013). The enormous worldwide costs of dementia are expected to rise in
the next few years. AD is becoming more prevalent due to the ageing of society and the lack of
effective drugs to improve or cure established disease. Currently, AD diagnosis is complex, costly and
inaccurate. Procedures including neuropsychological tests, magnetic resonance imaging and clinical
assessment are used to assist diagnosis but currently confirmation at autopsy is the only reliable way
to diagnose AD.
AD is characterized by protein misfolding commencing years before substantial neurodegeneration. It
can take over a decade to develop AD (Perrin et al., 2009; Price and Morris, 1999), making early
diagnosis possible and crucial. There are six isoforms of tau protein expressed in the human brain
(Goedert et al., 1989) which promote microtubule polymerization and stabilization in the nervous
system (Caceres and Kosik, 1990; Drubin and Kirschner, 1986; Goedert et al., 1989; Horio and
Hotani). Tau can undergo aberrant hyperphosphorylation at various sites and fail to stabilize the
microtubules, contributing to neurofibrillary tangles and paired helical filaments formation (Hanger et
al., 1998; Lu and Wood, 1993; Mandelkow and Mandelkow, 1998; von Linstow Roloff and Platt,
1999) which, alongside amyloid-beta (Aβ) plaques, are two prominent pathological hallmarks of AD 
(Brækhus, 2011; Kosik, 1991; Lee and Trojanowski, 1992). Historically, tau pathology was
considered secondary to Aβ pathology. However, the accumulation of abnormal tau species is now 
2known to more accurately predict disease severity (Cook et al., 2015). Both cognitive decline rate and
postmortem AD classification into pathological subtypes are determined by the tau pathology in the
brain (Murray et al., 2011). Tau levels in cerebro-spinal fluid (CSF) increase slightly with ageing.
Several studies demonstrated that CSF tau levels are significantly increased in AD patients (Brys et al.,
2009; H Hampel et al., 2004; Harald Hampel et al., 2004; Hu et al., 2002; Mandelkow and
Mandelkow, 1998; Mattsson et al., 2009; Shoji et al.), indicating tau as a critical biomarker for early
AD diagnosis. Sunderland et al (2003) demonstrated that a cut-off value of 4.3 pM tau in CSF can
differentiate AD cases with 92% sensitivity and 89% specificity (Sunderland et al.).
Tau CSF levels have been measured with conventional methods such as enzyme-linked
immunosorbent assay (ELISA), mass spectrometry or surface plasmon resonance, which are time-
consuming and/or expensive (Hye et al., 2014; Liu et al., 2014; Mehta et al., 2000; Sparks et al., 2012;
Tuantranont, 2013). Researchers have made great efforts to generate rapid, cost-effective and highly
sensitive detection tests using biosensors. For example, Rushworth et al. developed a label-free
electrochemical biosensor which detects Aβ oligomers (Rushworth et al., 2014). Recently, an 
electrochemical biosensor was developed for tau, although the level of detection is 0.2 µM - about 5
orders of magnitude higher than the CSF tau cut-off value (4.3 pM) which distinguishes AD cases
from control (Esteves-Villanueva et al., 2014).
In this study we have developed a novel, very sensitive electrochemical biosensor for detection of
full-length 2N4R tau protein based on a microelectrode array with four gold microband electrodes1
coated with oriented antibodies. The biosensor was specific for full-length tau detection with a limit
of quantification of 0.03 pM - much lower than the critical cut-off value (4.3 pM) of CSF tau protein.
We have also demonstrated the selectivity of this technique. The presence of bovine serum albumin
(BSA) has been shown to interfere with detection of low-abundant biomarkers in biological fluid
(Tuantranont, 2013). In this study, no significant interference from BSA or human serum (HS) was
observed. Although tau is the focus of this study, there is still not a consensus on the range of markers
associated with AD and this biosensor could be adapted to detect a range of such markers.
2. Materials and methods
2.1 Materials
The gold microband electrodes (AUMB4000-M) were manufactured by Windsor Scientific (UK).
3,3'-dithiobis(sulfosuccinimidyl propionate) (DTSSP), protein G, phosphate buffered saline (PBS),
sulphuric acid and Dulbecco's modified eagle medium (DMEM) were purchased from Thermo Fisher
Scientific (UK). Ethanolamine, BSA, skimmed milk powder, 3,3',5,5'-tetramethylbenzidine liquid
substrate and Tween20 were obtained from Sigma-Aldrich (UK). Anti-tau antibody (39E10) and
human full-length tau441 were from Cambridge Bioscience (UK). Polyvinylidene difluoride (PVDF)
membrane was purchased from Millipore Corporation, Bedford, MA, USA. Horseradish peroxidase
(HRP) conjugated anti-mouse antibody and HRP conjugated anti-His antibody were purchased from
Abcam, UK. HS taken from confirmed normal individuals was purchased from BBI Solutions, UK.
2.2 Development of the biosensor
The biosensor was developed on a microelectrode array (from Windsor Scientific, UK) composed of
four gold microband electrodes fabricated using standard microfabrication technology on a p-doped
1 The tetrapolar technique (four electrodes) has the advantage that the electrode configuration can be adjusted to
maximise the sensitivity of the impedance change in different biological and chemical layers. More importantly,
unlike the three electrode method used in Sharma et al. 2016, the tetrapolar method improves the sensitivity of
the voltage measurement obtained from the tau layer (Kassanos et al., 2008a).
3silicon substrate (Fig. 1). The gold surface was coated with an organic polymer passivation layer,
leaving an open window of 1 × 1 mm exposing a 1 mm length of each gold microband electrode - the
active area.
The microelectrode array was connected to a printed circuit board via four gold-plated pins and then
to the appropriate BNC socket of the impedance analyser. The first electrode was the working
electrode (WE), to which the signal generator output of the impedance analyser was connected. The
fourth electrode was the counter electrode (CE). This was connected to the instrument’s current input
BNC socket. The second and third electrodes were reference electrodes (RE) and were connected
respectively to the instrument’s V1 Hi and V1 Lo BNCs (Fig. 1). A shield was used to protect the
measurements from external electromagnetic noise.
The gold microband electrodes were washed with 5 mL of 100% ethanol, de-ionized water and PBS
to remove any dielectric material from the sensor surface. Cross-linker DTSSP was attached to the
cleaned microband electrodes by dissociative chemisorbtion forming a self-assembled monolayer
(SAM). Protein G and antibodies were added layer by layer, incubating each for 45 min in PBS, with
washing steps in between. DTSSP attaches protein G via the interaction between the sulpho-NHS
ester and amino groups. Ethanolamine was used to saturate unreacted sulpho-NHS ester group in
DTSSP after protein G binding before addition of antibody. Different concentrations of anti-tau
antibody were applied (see supporting information, Fig. S1). The optimal concentration of 125 µg/ml
of anti-tau antibody was used throughout the following experiments.
2.3 Electrochemical impedance spectroscopy (EIS)
At each stage of biosensor assembly, impedance measurements were conducted in 10 mM
K4Fe(CN)6/K3Fe(CN)6 (1:1 ratio) in PBS pH 7 using Smart software on a Solartron Impedance/Gain-
Phase Analyser 1260 model (Solartron Analytical, UK). A sinusoidal signal of 5 mV amplitude was
applied between electrodes WE and CE (Fig. 1) using a frequency range 40-40,000 Hz to produce EIS
measurements. The fully built biosensor was subjected to successive incubations in tau or BSA (10-
14 M, 10-12 M, 10-10 M, 10-8 M, and 10-7 M) for 25 min at room temperature. After each reaction, the
biosensor electrodes were flood washed with 5 mL of de-ionized water and PBS before recording the
impedance in 10 mM K4Fe(CN)6/K3Fe(CN)6 (1:1 ratio) in PBS pH 7 as described above. EIS
parameters Rs (solution resistance), Rct (charge-transfer resistance or interfacial resistance) and Cp
(constant phase element, an equivalent model of double-layer capacitance) were generated by fitting
the data to the Randles′ equivalent circuit model using Zview software (Solartron Analytical, UK). 
2.3 Cyclic voltammetry
Cyclic voltammetry (CV) was performed in sulphuric acid for electrode regeneration and in 10 mM
K4Fe(CN)6/K3Fe(CN)6 (1:1 ratio) in PBS pH 7 for the biosensor layer-by-layer construction. For
electrode regeneration, the potential was cycled from -0.1 V to +1.74 V at 100 mV s-1 SCE (saturated
calomel electrode) 4 or 5 times to remove surface analytes and/or contaminants. For biosensor
construction, scans were conducted between -0.4 V and +0.8 V.
2.4 Tau detection by Western blotting
Following electrophoresis, proteins were transferred to an activated PVDF membrane. Transfer was
carried out in a Trans-Blot Semi-Dry transfer machine (Bio-Rad Laboratories, Hercules, CA, USA)
and run at 50 mA for 90 min. Membranes were incubated in 5% skimmed milk in PBS-0.1%
Tween20 (PBST) at room temperature for 1 h prior to incubation in primary mouse anti-tau antibody
(39E10) diluted 1:1000 with 1% milk in PBST for 1 h at room temperature. This was followed by
three 15 min washes in PBST. HRP conjugated anti-mouse antibody was diluted 1:5000 with 1% milk
4in PBST and incubated with membrane for 1 h at room temperature. Membranes were then washed
three times as before. Proteins were visualised by chemiluminescence detection with ECL PLUS
(Amersham Pharmacia Biotech, Piscataway, NJ, USA) for 5 min and analyzed using the LI-COR
system (LI-COR Biosciences, USA).
2.5 ELISA
ELISA was carried out to determine the interaction between tau antibody (39E10) and tau. 1 µg/mL
39E10 was coated on 96-well Maxisorp plates (NUNC. Denmark) at 4 oC overnight. After blocking
with 200 µL/well Microwell Blocking Buffer with Stabilizer (Rockland), serial dilutions of tau in
PBS or tau in 5% HS pH 7, were added to the plates for 1 h. After three washes with PBS, HRP
conjugated anti-His antibody (1:2500 dilution) was added to detect the bound tau. 3,3',5,5'-
tetramethylbenzidine liquid substrate was added and left to develop for 30 min at room temperature.
The reaction was stopped with 2M sulphuric acid and absorbance measured at 450 nm.
3. Results
3.1. Confirmation of biosensor assembly by EIS and CV
The biosensor was constructed on four gold microband electrodes (Fig. 1). SAM was deposited as
described in Section 2.2 after the gold electrodes were cleaned with ethanol, followed by incubation
with protein G and antibodies for 45 min in PBS, with washing in between. We adapted the
construction of our previous biosensor (Kassanos et al., 2008b) using a layer of protein G, to ensure
that antibody Fab binding domains were oriented away from the biosensor surface and free to react
with target antigens. This increases the loading capacity of the biosensor and its sensitivity to antigens.
Additionally, it significantly improves reproducibility, since the antibodies do not attach randomly to
the surface.
EIS is widely used to validate the layer-by-layer deposition of materials to a sensor surface because it
is a very powerful tool for surface interface characterization and detection of changes to biosensor
surfaces (Bryan et al., 2012; Rushworth et al., 2014). Here, impedance measurements were performed
at each stage of the assembly in 10 mM K4Fe(CN)6/K3Fe(CN)6 (1:1 ratio) in PBS pH 7 over a
frequency range 40-40,000 Hz. These spectra are typical of the theoretical, semi-circular shape when
fitted to a Randles′ equivalent circuit (a useful tool in interpreting EIS data which accounts for the 
resistive and capacitive processes at different frequencies). An example of Nyquist plots of the
measured EIS data from a sample biosensor is shown in Fig. 2A. Fitting the data to the Randles′ 
equivalent circuit model, demonstrated that the interfacial charge-transfer resistance (Rct) changed
after each layer was deposited (Fig. 2B), namely bare gold, DTSSP or SAM, protein G, ethanolamine
and antibody. This indicates the successful construction of the biosensor. It is widely reported that
analyte binding to biosensor surfaces often causes increased impedance, typically due to increasing
deposition of a substance on the sensor surface which increases its surface capacitance and resistance
(Martic et al., 2013). However, although less widely reported, the binding of certain analytes to
electrochemical biosensors can decrease the surface impedance (Rushworth et al., 2014). The same
reaction was observed here. The attachment of anti-tau to the functionalised surface may increase the
conductivity of the surface and thus cause a decrease in impedance change (Fig. 2B). The construction
of the biosensor and the assembly of each layer were also confirmed by CV (Fig. 2C).
53.2. Detection of tau by the biosensor
The biosensor was incubated with successive concentrations of tau (10-14 M to 10-7 M) for 25 min
each, followed by flood washing with dH2O and PBS. Impedance was recorded with the biosensor
immersed in 10 mM K4Fe(CN)6/K3Fe(CN)6 (1:1 ratio) in PBS pH 7 over a frequency range of 40-
40,000 Hz. The measured EIS data from a sample biosensor are presented as Nyquist plots in Fig. 3.
Generated EIS parameters Rs (solution resistance), Rct (charge-transfer resistance) and Cp (constant
phase element, an equivalent model of double-layer capacitance) after fitting the data to the Randles′ 
equivalent circuit, are listed in Table 1. Rct was the parameter used to evaluate analyte-biosensor
binding in the experiments because it is based on Faradaic impedance, measured in the presence of
redox mediators (Rushworth et al., 2014). Rct values increased upon addition of increasing
concentrations of tau (10-14 M to 10-7 M) as demonstrated by the increasing height and diameter of the
semi-circular Nyquist traces (Fig. 3A), corresponding to increased capacitance and resistance of the
sensor surface respectively. As reported before, the binding of analyte to a biosensor surface often
causes an increase in impedance (Martic et al., 2013; Rains et al., 2013).
3.3. Calibration curves of tau binding to the biosensor
Biosensor specificity and selectivity were analysed by incubation with BSA - a commonly used
plasma protein standard. Albumin is the most-abundant protein component in serum and CSF.
Multiple biosensors (n ≥ 3) were incubated in the presence of either tau or BSA (negative control) as 
described in Section 2.2. The Rct values for each analyte concentration were calculated by fitting
semi-circle spectra to the Randles′ equivalent circuit model. The Rct values following incubation with
increasing concentrations of tau and BSA are shown in Fig. 3B. There was a trend of increasing
interfacial resistance after tau binding, while no significant response was detected following BSA
incubation. The Rct value for tau binding reached a plateau with no further increase at 10-8 M
indicating saturation of the biosensor interfacial surface. The inset in Fig. 3B demonstrates the
relationship between interfacial resistance change and tau concentrations (0.01 pM to 10 nM)
constructed from Rct values from at least three independent experiments. The biosensor response to
tau was quantified as (Rct – Rct0)/Rct0, where Rct0 represents the Rct value of biosensor with antibody
deposition. The limit of detection (LOD) calculated according to IUPAC (International Union of Pure
and Applied Chemistry) was 0.03 pM (Loo et al., 2014).
The selectivity and specificity of tau antibody was investigated by Western blotting (Fig. 3C inset).
Different concentrations of tau in PBS or HS were transferred to PVDF membrane before incubation
with anti-tau antibody and HRP conjugated anti-mouse antibody as described in Section 2.2. ECL
reagent was used to generate a chemiluminescent signal. An increasing signal was detected for
increasing tau concentrations, while no signal was detected with HS only (Fig. 3C inset), indicating
the tau specificity. Specificity was further confirmed by incubating multiple biosensors (n ≥ 3) with 
BSA. The biosensor was unresponsive to BSA incubation (10-14 M to 10-6 M, Fig. 3C). The
percentage change of Rct was < 4% at 10-6 M BSA, compared to > 60% at a tau concentration of 10-
14 M.
3.4. Validation of the biosensor using human serum (HS) spiked with tau
Finally, we evaluated the ability of the biosensor to detect tau in HS. Serum spiked with different tau
concentrations was incubated with the biosensor and EIS was conducted in 10 mM
K4Fe(CN)6/K3Fe(CN)6 (1:1 ratio) pH 7 under standard conditions over a frequency range of 40-
40,000 Hz as described in Section 2.2. The trend of biosensor response to tau in HS in Nyquist plots
6(Fig. 4) was similar to that seen for tau only (Fig. 3), indicating that the biosensor specifically
recognizes tau at 10-14 M in HS. Biosensor response was not affected following incubation with HS at
a range of dilutions in PBS indicating that components of serum do not interfere with tau
measurement (Fig. 4B). Although the % change of Rct versus full biosensor (Rct0) was lower than that
for tau only, the relative increase (three fold) was similar between the tau concentration range of 10-14
and 10-8 M for tau in PBS (0.6-1.6) (Fig. 3B) and tau in a dilution of 1:1 in HS (0.08-0.29) (Fig. 4C),
indicating that HS did not affect assay specificity or sensitivity. The low change of Rct may be due to
the small electrode size and non-specific interference of HS to the biosensor also seen in ELISA (Fig.
5A).
3.5. Comparison between electrochemical biosensor and ELISA
ELISA was carried out to determine the LOD of tau by anti-tau antibody. LOD was defined as the
lowest concentration of tau that was distinguishable from HS in the absence of tau. ELISA took
several hours while the electrochemical biosensor testing took less than 1 h for incubation and
measurement. The LOD by the biosensor (10-14 M) was greatly superior to that for ELISA (10-8 M) as
shown in Fig. 5.
4. Conclusions and future work
In this study, we extended the development of a novel electrochemical biosensor based on tetrapolar
EIS, which allows adjustment of the sensitivity of detection of different layers of material binding to
the electrode surface (Kassanos et al., 2008b). Our data indicate that the sensor can rapidly detect tau
as low as 0.03 pM which is much lower than the detection limit of ELISA in this study (10 nM) and
the commercial ELISA kit (Thermofisher Scientific, UK, 0.25 pM), both of which take at least 4 h to
complete. The specificity of the bioreceptor for tau binding was confirmed by Western blotting. The
results suggest that the biosensor could be used to quantify tau in CSF and serum.
We have validated this biosensor for measurement in both serum and PBS buffer. In a previous study
examining AD biomarkers from CSF (Rushworth et al 2014), it was observed that serum and CSF are
complex media but provide comparable results. We believe that this is a good indication that the
biosensor in this study will perform equally well in CSF. Crucially, in our biosensor we have also
demonstrated that albumin, the most abundant protein component of both serum and CSF, does not
interfere with tau measurement. It would, of course, be of interest to compare the performance of this
method in CSF.
Compared to previous biosensors for tau detection (Esteves-Villanueva et al., 2014), ours is extremely
sensitive, highly specific and allows detection in HS down to 0.03 pM which is diagnostically
important for AD. It was noted that there is a variation in the response of PBS to HS for the biosensor.
It is likely that this is due to a variation of the ion concentration in the different media, which could be
addressed by using different electrode spacing for different media. There is scope to further improve
the biosensor characteristics by increasing the electrode surface area and using Fab fragments as
bioreceptors. The utilization of protein G and antibodies of differing specificities would enable the
development of a multiplex device where multiple biosensors functionalized with different
bioreceptors could be employed for simultaneous detection of multiple AD biomarkers.
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9Fig. 1. (A) Details of the purchased gold microband electrodes. It shows the 1 × 1 mm active sensor area and the
connections to the impedance analyser. (B) Schematic side view of the biosensor. From bottom to top: gold
microband electrode, SAM layer, protein G layer and antibodies. (C) Chemical structure of DTSSP which
contains an amine-reactive N-hydroxysulfosuccinimide (sulfo-NHS) ester at each end and forms the SAM layer.
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Fig. 2. Construction and assembly of the biosensor. (A) Layer-by-layer development of the biosensor verified
by EIS. The imaginary component of impedance (Z″) was plotted against the real component of impedance (Z′) 
in Nyquist plots. Impedance spectra were recorded after each construction stage: (a) bare gold, (b) DTSSP or
SAM, (c) protein G, (d) ethanolamine and (e) anti-tau antibody, in 10 mM K4Fe(CN)6/K3Fe(CN)6 (1:1 ratio) in
PBS pH 7 over a frequency range of 40-40,000 Hz. Inset shows the Randles′ equivalent circuit model t of the 
impedance used for fitting where Rs = solution resistance, Rct = charge-transfer resistance and Cp = constant
phase element. (B) Interfacial charge-transfer resistance (Rct) variance across the different functionalization
steps. (C) Characterization of layer-by-layer construction of the biosensor verified by CV as described in
Section 2.2.
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Fig. 3. Biosensor response to increasing tau concentrations measured by EIS. (A) EIS analysis of cumulative
incubations with tau (10-14 M to 10-7 M) in PBS followed by rinsing with dH2O and PBS in 10 mM
K4Fe(CN)6/K3Fe(CN)6 (1:1 ratio) in PBS pH 7 over a frequency range of 40-40,000 Hz. Impedance
measurements are presented as Nyquist plots with the imaginary component of impedance (Z″) plotted against 
the real component of impedance (Z′). Inset shows impedance spectra fitted into a Randles′ equivalent circuit 
model where Rs = solution resistance, Rct = charge-transfer resistance and Cp = constant phase element. (B)
Calibration curves of tau binding to the biosensor. The charge-transfer resistance (Rct) values of the anti-tau
antibody interfaces following incubation with tau or BSA were determined by fitting the data to the Randles′ 
circuit model using Zview software. Rct values for tau and BSA were compared using a two tails t-test assuming
unequal variances, *p < 0.05. Inset figure shows percentage of Rct change of equilibrated biosensor (Rct0) after
incubation with increasing tau concentrations. (C) Influence of increasing BSA concentrations on biosensor
response in PBS containing 10 mM K4Fe(CN)6/K3Fe(CN)6 (1:1 ratio) pH 7. A change of < 4% in Rct was seen at
10-6 M BSA compared to more than 60% change at 10-14 M tau. The horizontal line shows the response to 10-
14 M tau. Inset figure showed detection of 0.05 to 0.2 µg of tau in PBS or in 5% HS by anti-tau antibody by
Western blotting.
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Fig. 4. Biosensor response to (A) tau spiked in HS, and (B) HS in a range of dilutions 1:1 to 1:1000 as measured
by EIS. EIS analysis of biosensor of incubations with tau (10-14 M to 10-7 M) in HS followed by rinsing with
dH2O and PBS, in 10 mM K4Fe(CN)6/K3Fe(CN)6 (1:1 ratio) in PBS pH 7 over a frequency range of 40-
40,000 Hz. Impedance measurements were presented as Nyquist plots where the imaginary component of
impedance (Z″) was plotted against the real component of impedance (Z′). (C) Calibration curves of tau in a 
dilution of 1:1 HS binding to the biosensor. The % Rct change versus full biosensor (Rct0) after incubation with
different tau concentrations in HS were presented as the mean of at least three independent experiments ± SD.
The charge-transfer resistance (Rct) values of the anti-tau antibody interfaces following incubation with tau were
determined by fitting the data to the Randles′ circuit model using Zview software. These Rct values were
compared statistically for tau and HS only using two tailed t-test assuming unequal variances, *p < 0.05,
**p < 0.005, ***p < 0.001. The horizontal red line shows the biosensor response to HS only.
13
Assay method LOD (M) Assay range (M)
Biosensor 10-14 10-14 ~ 10-7
ELISA 10-8 10-12 ~ 10-7
Fig. 5. Comparison of LOD of tau by ELISA and electrochemical biosensor methods. LOD from biosensor was
six orders of magnitude lower than for ELISA. (A) ELISA results showing detection of different tau
concentrations (10-12 M to 10-7 M) in PBS or in 5% HS. (B) Biosensor results showing detection of 10-14 M to
10-7 M tau in PBS and HS.
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Table1.
EIS parameters obtained from fitting the Nyquist plots shown in Fig. 3A to the Randles′ circuit model. The data 
is presented with standard error.
Electrode Rs (Ω) Cp (nF) Rct (Ω) 
Biosensor 130.6±1.9 159.7±2.9 592.3±14.3
Tau 10-14 M 139.2±2.0 159.7±2.8 647.1±16.9
Tau 10-12 M 150.0±2.2 156.6±2.6 844.1±24.5
Tau 10-10 M 142.8±2.0 154.6±2.0 1266.0±39.4
Tau 10-8 M 125.6±1.5 128.5±1.3 1789.0±53.0
Tau 10-7 M 119.0±1.1 123.5±9.3 1739.0±37.8
